Clinical Study of Individualized Vancomycin Dosing Based on Population PK Model
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare the clinical efficacy of individualized dosing
based on the population pharmacokinetics (PK) model and empirical dosing of vancomycin in
participants with severe infections.
It aims to answer whether individual vancomycin dosing based on population PK model is
superior to empirical dosing in terms of clinical efficacy and safety.
Participants will be randomly divided into experimental group and control group. The
experimental group will be guided by the population PK model for individual dosing, and the
control group will be given empirical dosing. Demographic data, clinical characteristics of
participants, and their trough concentrations (Cmin) and peak concentrations (Cmax) of
vancomycin will be collected. Area under the concentration curve (AUC24) of participants will
be calculated using the first-order PK equation.
Researchers will compare experimental group and control group to see if individual vancomycin
dosing based on population PK model is superior to empirical dosing in terms of clinical
efficacy and safety.